Clinical Trial

Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 2, 2025 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, open-label, phase II study evaluating the efficacy and safety of Trastuzumab Rezetecan in combination with pertuzumab in early or locally advanced HER2-positive breast cancer.
Trial Details
NCT Number NCT07047755
Lead Sponsor Henan Cancer Hospital
Conditions Breast Cancer
Enrollment 48 participants
Start Date 2025-07-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2031-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-07-02